ARVN901 (AE-101) is a novel cell-injection therapy developed using cultured human corneal endothelial cells (hCECs) combined with a Rho-associated kinase (ROCK) inhibitor. Studies , have demonstrated that the injection of hCECs supplemented with a ROCK inhibitor has strong efficacy and safety profiles in patients with corneal endothelial dysfunction. The ground-breaking clinical research findings published in the New England Journal of Medicine and Ophthalmology led by ActualEyes’ scientific founders, Dr. Noriko Koizumi and Dr. Naoki Okumura, have shown that AE-101 can effectively restore corneal endothelial function as well as vision, with no major treatment-relevant adverse reactions for up to 5-years post-operation, which represents a paradigm shift in corneal regenerative medicine.
1 Kinoshita, Shigeru & Koizumi, Noriko et al. (2018). Injection of Cultured Cells with a ROCK Inhibitor for Bullous Keratopathy. The New England journal of medicine. 378. 995-1003. 10.1056/NEJMoa1712770.
2 Numa, Kohsaku & Imai, Kojiro et al. (2020). Five-Year Follow-up of First Eleven Cases Undergoing Injection of Cultured Corneal Endothelial Cells for Corneal Endothelial Failure. Ophthalmology. 128. 10.1016/j.ophtha.2020.09.002.